BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/4/2026 3:47:10 AM | Browse: 1 | Download: 6
 |
Received |
|
2026-07-01 06:00 |
|
Peer-Review Started |
|
2026-07-01 06:01 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-08-06 16:59 |
|
Revised |
|
2026-08-25 23:03 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-10-09 03:30 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-10-09 09:02 |
|
Articles in Press |
|
2026-10-09 09:02 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-10-12 02:02 |
|
Publish the Manuscript Online |
|
2026-11-04 03:47 |
| ISSN |
2220-6132 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Minireviews |
| Article Title |
Molecular mechanisms of BCR::ABL1 in chronic myeloid leukaemia: From treatment-free remission to curative therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Temilola Oludunmomi Owojuyigbe and Muheez Alani Durosinmi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Temilola Oludunmomi Owojuyigbe, Assistant Professor, Consultant, Lecturer, MD, PhD, Department of Haematology and Immunology, Obafemi Awolowo University, Faculty of Basic Clinical Sciences College of Health Sciences, Ile-Ife 220, Osun, Nigeria. temilolly@yahoo.com |
| Key Words |
Chronic myeloid leukaemia; BCR::ABL1; Tyrosine kinase inhibitor; Drug resistance; Treatment-free remission; Leukaemia stem cells; Cure |
| Core Tip |
Chronic myeloid leukaemia is a clonal haematological malignancy with a well-defined aetiology: The Philadelphia chromosome. The backbone of therapy are the tyrosine kinase inhibitors (TKIs) which have transformed the disease from a fatal cancer into a manageable, chronic disease. The TKIs produced remarkable cytogenetic and molecular remission but they do not produce cure in about half of the patients due to the non-eradication of leukaemia stem cells. This review evaluates the molecular mechanisms underlying BCR::ABL1 signalling and leukaemia stem cell survival, providing a framework that distinguishes guideline-supported operational remission from investigational “double-hit” therapies aimed at leukaemic clone eradication. |
| Publish Date |
2026-11-04 03:47 |
| Citation |
Owojuyigbe TO, Durosinmi MA. Molecular mechanisms of BCR::ABL1 in chronic myeloid leukaemia: From treatment-free remission to curative therapy. World J Transl Med 2026; 12(4): 125122
|
| URL |
https://www.wjgnet.com/2220-6132/full/v12/i4/125122.htm |
| DOI |
https://doi.org/10.5528/wjtm.125122 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
